AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings of claims in the application.

In the Claims

Claim 1 (previously presented): A pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin in an amount effective to reduce one or more side effects of administration of the pharmaceutical agent into a human, wherein the pharmaceutically acceptable carrier comprises deferoxamine in an amount effective to inhibit microbial growth in the pharmaceutical composition and wherein the pharmaceutical agent is selected from the group consisting of paclitaxel, docetaxel, taxanes, camptothecin, propofol, amiodarone, cyclosporine, rapamycin, amphotericin, liothyronine, epothilones, colchicines, thyroid hormones, vasoactive intestinal peptide, corticosteroids, melatonin, tacrolimus, mycophenolic acids.

Claim 2 (cancelled).

Claim 3 (cancelled).

Claim 4 (previously presented): The pharmaceutical composition of claim 1, wherein the pharmaceutical agent is propofol.

Claim 5 (original): The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is a liquid and comprises from about 0.1% to about 25% by weight of albumin.

Claim 6 (original): The pharmaceutical composition of claim 5, wherein the pharmaceutical composition comprises about 0.5% to about 5% by weight of albumin.

Claim 7 (previously presented): The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is dehydrated.

Claim 8 (original): The pharmaceutical composition of claim 6, wherein the pharmaceutical composition is lyophilized.

Claim 9 (original): The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises a mesylate salt of deferoxamine.

Claim 10 (original): The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is a liquid and comprises from about 0.0001% to about 0.5% by weight of deferoxamine mesylate.

Claim 11 (original): The pharmaceutical composition of claim 10, wherein the pharmaceutical composition comprises about 0.1% by weight of deferoxamine mesylate.

Claim 12 (previously presented): The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is dehydrated.

Claim 13 (original) The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is lyophilized.

Claim 14 (original): The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is an oil-in-water emulsion.

Claim 15 (original): The pharmaceutical composition of claim 5, wherein the pharmaceutical agent is propofol.

Claim 16 (original): The pharmaceutical composition of claim 10, wherein the pharmaceutical agent is propofol.

Claim 17 (Original): The pharmaceutical composition of claim 9, wherein the pharmaceutical agent is propofol, the propofol is present in an amount from about 0.1% to about 5%

by weight, the albumin is present in an amount from about 0.1% to about 25% by weight, and the deferoxamine mesylate is present in an amount from about 0.0001% to about 0.5% by weight.

Claim 18 (Previously presented): A pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin in an amount effective to reduce one or more side effects of administration of the pharmaceutical agent into a human, wherein the pharmaceutically acceptable carrier comprises deferoxamine in an amount effective to inhibit oxidation in the pharmaceutical composition and wherein the weight ratio of albumin to pharmaceutical agent is about 18:1 or less.

Claims 19-83 (Cancelled).

Claim 84 (Previously presented): A pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin in an amount effective to reduce one or more side effects of administration of the pharmaceutical agent into a human, wherein the pharmaceutically acceptable carrier comprises deferoxamine in an amount effective to inhibit microbial growth in the pharmaceutical composition, and wherein the weight ratio of albumin to pharmaceutical agent is about 18:1 or less.

Claims 85-96 (Cancelled).

Claim 97 (Previously presented): The pharmaceutical composition of claim 1, wherein the albumin and the pharmaceutical agent in the composition are formulated as nanoparticles.

Claim 98 (Previously presented): The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is free of Cremophor.

Claim 99 (Previously presented): The pharmaceutical composition of claim 1, wherein the albumin is human serum albumin.

Claim 100 (Previously presented): The pharmaceutical composition of claim 1, wherein the pharmaceutical agent is a taxane.

Claim 101 (Previously presented): The pharmaceutical composition of claim 100, wherein the taxane is paclitaxel.

Claim 102 (Previously presented): The pharmaceutical composition of claim 100, wherein the taxane is docetaxel.

Claim 103 (Previously presented): A pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin in an amount effective to reduce one or more side effects of administration of the pharmaceutical agent into a human, wherein the pharmaceutically acceptable carrier comprises deferoxamine in an amount effective to inhibit microbial growth in the pharmaceutical composition, wherein the pharmaceutical composition comprises about 1% to about 25% by weight of albumin, and wherein the pharmaceutical composition is dehydrated.

Claim 104 (currently amended): The pharmaceutical composition of claim ~~116~~ 103, wherein the pharmaceutical composition is lyophilized.

Claim 105 (previously presented): A pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin in an amount effective to reduce one or more side effects of administration of the pharmaceutical agent into a human, wherein the pharmaceutically acceptable carrier comprises deferoxamine in an amount effective to inhibit microbial growth in the pharmaceutical composition, wherein the pharmaceutical composition comprises about 0.0001% to about 0.5% by weight of deferoxamine mesylate, and wherein the pharmaceutical composition is dehydrated.

Claim 106 (Currently amended): The pharmaceutical composition of claim ~~118~~ 105, wherein the pharmaceutical composition is lyophilized.

Claim 107 (Previously presented): A pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin in an amount effective to reduce one or more side effects of administration of the pharmaceutical agent into a human, wherein the pharmaceutically acceptable carrier comprises deferoxamine in an amount effective to inhibit microbial growth in the pharmaceutical composition, and wherein the pharmaceutical composition is oil-in-water emulsion.

Claim 108 (Previously presented): The pharmaceutical composition of claim 18, wherein the weight ratio of albumin to pharmaceutical agent is about 15:1 or less.

Claim 109 (Previously presented): The pharmaceutical composition of claim 108, wherein the weight ratio of albumin to pharmaceutical agent is about 9:1 or less.

Claim 110 (Previously presented): The pharmaceutical composition of claim 109, wherein the weight ratio of albumin to pharmaceutical agent is from about 1:1 to about 9:1.

Claim 111 (Previously presented): The pharmaceutical composition of claim 18, wherein the albumin and the pharmaceutical agent in the composition are formulated as nanoparticles.

Claim 112 (Previously presented): The pharmaceutical composition of claim 18, wherein the pharmaceutical composition is free of Cremophor.

Claim 113 (previously presented): The pharmaceutical composition of claim 18, wherein the albumin is human serum albumin.

Claim 114 (previously presented): The pharmaceutical composition of claim 18, wherein the pharmaceutical agent is selected from the group consisting of paclitaxel, docetaxel, taxanes, camptothecin, propofol, amiodarone, cyclosporine, rapamycin, amphotericin, liothyronine, epothilones, colchicines, thyroid hormones, vasoactive intestinal peptide, corticosteroids, melatonin, tacrolimus, mycophenolic acids.

Claim 115 (previously presented): The pharmaceutical composition of claim 114, wherein the pharmaceutical agent is a taxane.

Claim 116 (previously presented): The pharmaceutical composition of claim 115, wherein the taxane is paclitaxel.

Claim 117 (previously presented): The pharmaceutical composition of claim 116, wherein the weight ratio of albumin to paclitaxel is about 15:1 or less.

Claim 118 (previously presented): The pharmaceutical composition of claim 117, wherein the weight ratio of albumin to paclitaxel is about 9:1 or less.

Claim 119 (previously presented): The pharmaceutical composition of claim 118, wherein the weight ratio of albumin to paclitaxel is about 1:1 to about 9:1.

Claim 120 (previously presented): The pharmaceutical composition of claim 116, wherein the albumin and the paclitaxel in the composition are formulated as nanoparticles.

Claim 121 (previously presented): The pharmaceutical composition of claim 116, wherein the pharmaceutical composition is free of Cremophor.

Claim 122 (previously presented): The pharmaceutical composition of claim 116, wherein the albumin is human serum albumin.

Claim 123 (previously presented): The pharmaceutical composition of claim 115, wherein the taxane is docetaxel.

Claim 124 (previously presented): The pharmaceutical composition of claim 123, wherein the weight ratio of albumin to docetaxel is about 15:1 or less.

Claim 125 (previously presented): The pharmaceutical composition of claim 123, wherein the albumin is human serum albumin.

Claim 126 (previously presented): The pharmaceutical composition of claim 123, wherein the albumin and the docetaxel in the composition are formulated as nanoparticles.

Claim 127 (previously presented): The pharmaceutical composition of claim 123, wherein the pharmaceutical composition is free of Cremophor.

Claim 128 (previously presented): The pharmaceutical composition of claim 84, wherein the weight ratio of albumin to pharmaceutical agent is about 15:1 or less.

Claim 129 (previously presented): The pharmaceutical composition of claim 128, wherein the weight ratio of albumin to pharmaceutical agent is about 9:1 or less.

Claim 130 (Previously presented): The pharmaceutical composition of claim 129 wherein the weight ratio of albumin to pharmaceutical agent is from about 1:1 to about 9:1.

Claim 131 (Previously presented): The pharmaceutical composition of claim 84, wherein the albumin and the pharmaceutical agent in the composition are formulated as nanoparticles.

Claim 132 (Previously presented): The pharmaceutical composition of claim 84, wherein the pharmaceutical composition is free of Cremophor.

Claim 133 (Previously presented): The pharmaceutical composition of claim 84, wherein the albumin is human serum albumin.

Claim 134 (Previously presented): The pharmaceutical composition of claim 84, wherein the pharmaceutical agent is selected from the group consisting of paclitaxel, docetaxel, taxanes, camptothecin, propofol, amiodarone, cyclosporine, rapamycin, amphotericin, liothyronine, epothilones, colchicines, thyroid hormones, vasoactive intestinal peptide, corticosteroids, melatonin, tacrolimus, mycophenolic acids.

Claim 135 (Previously presented): The pharmaceutical composition of claim 134, wherein the pharmaceutical agent is a taxane.

Claim 136 (Previously presented): The pharmaceutical composition of claim 135, wherein the taxane is paclitaxel.

Claim 137 (previously presented): The pharmaceutical composition of claim 136, wherein the weight ratio of albumin to paclitaxel is about 15:1 or less.

Claim 138 (previously presented): The pharmaceutical composition of claim 137, wherein the weight ratio of albumin to paclitaxel is about 9:1 or less.

Claim 139 (previously presented): The pharmaceutical composition of claim 138, wherein the weight ratio of albumin to paclitaxel is about 1:1 to about 9:1.

Claim 140 (Previously presented): The pharmaceutical composition of claim 136, wherein the albumin and the paclitaxel in the composition are formulated as nanoparticles.

Claim 141 (previously presented): The pharmaceutical composition of claim 136, wherein the pharmaceutical composition is free of Cremophor.

Claim 142 (previously presented): The pharmaceutical composition of claim 136, wherein the albumin is human serum albumin.

Claim 143 (previously presented): The pharmaceutical composition of claim 135, wherein the taxane is docetaxel.

Claim 144 (previously presented):The pharmaceutical composition of claim 143, wherein the weight ratio of albumin to docetaxel is about 15:1 or less.

Claim 145 (previously presented): The pharmaceutical composition of claim 143, wherein the albumin and the docetaxel in the composition are formulated as nanoparticles.

Claim 146 (previously presented): The pharmaceutical composition of claim 143, wherein the pharmaceutical composition is free of Cremophor.

Claim 147 (previously presented): The pharmaceutical composition of claim 143, wherein the albumin is human serum albumin.

Claim 148 (previously presented): The pharmaceutical composition of claim 97, wherein the nanoparticles have a mean size of less than about 200 nm.

Claim 149 (previously presented): The pharmaceutical composition of claim 111, wherein the nanoparticles have a mean size of less than about 200 nm.

Claim 150 (previously presented): The pharmaceutical composition of claim 120, wherein the nanoparticles have a mean size of less than about 200 nm.

Claim 151 (previously presented): The pharmaceutical composition of claim 126, wherein the nanoparticles have a mean size of less than about 200 nm.

Claim 152 (previously presented): The pharmaceutical composition of claim 131, wherein the nanoparticles have a mean size of less than about 200 nm.

Claim 153 (previously presented): The pharmaceutical composition of claim 140, wherein the nanoparticles have a mean size of less than about 200 nm.

Claim 154 (previously presented): The pharmaceutical composition of claim 145, wherein the nanoparticles have a mean size of less than about 200 nm.

Claim 155 (new): The pharmaceutical composition of claim 1, wherein the pharmaceutical agent is rapamycin.

Claim 156 (new): The pharmaceutical composition of claim 97, wherein the pharmaceutical agent is rapamycin.

Claim 157 (new): The pharmaceutical composition of claim 148, wherein the pharmaceutical agent is rapamycin.

Claim 158 (new): The pharmaceutical composition of claim 1, wherein the pharmaceutical agent is vasoactive intestinal peptide.

Claim 159 (new): The pharmaceutical composition of claim 97, wherein the pharmaceutical agent is vasoactive intestinal peptide.

Claim 160 (new): The pharmaceutical composition of claim 148, wherein the pharmaceutical agent is vasoactive intestinal peptide.

Claim 161 (new): The pharmaceutical composition of claim 18, wherein the pharmaceutical agent is selected from the group consisting of anticancer agents, anesthetics, antimicrotubule agents, agents to treat cardiovascular disorders, antihypertensives, anti-inflammatory agents, anti-arthritic agents, antiasthmatics, analgesics, vasoactive agents, immunosuppressive agents, antifungal agents, antiarrhythmic agents, antibiotics, and hormones.

Claim 162 (new): The pharmaceutical composition of claim 161, wherein the pharmaceutical agent is an anticancer agent.

Claim 163 (new): The pharmaceutical composition of claim 161, wherein the pharmaceutical agent is an anti-inflammatory agent.

Claim 164 (new): The pharmaceutical composition of claim 161, wherein the pharmaceutical agent is an immunosuppressive agent.

Claim 165 (new): The pharmaceutical composition of claim 161, wherein the pharmaceutical agent is an antibiotic.

Claim 166 (new): The pharmaceutical composition of claim 161, wherein the pharmaceutical agent is rapamycin.

Claim 167 (new): The pharmaceutical composition of claim 161, wherein the pharmaceutical agent is vasoactive intestinal peptide.

Claim 168 (new): The pharmaceutical composition of claim 111, wherein the pharmaceutical agent is selected from the group consisting of anticancer agents, anesthetics,

antimicrotubule agents, agents to treat cardiovascular disorders, antihypertensives, anti-inflammatory agents, anti-arthritic agents, antiasthmatics, analgesics, vasoactive agents, immunosuppressive agents, antifungal agents, antiarrhythmic agents, antibiotics, and hormones.

Claim 169 (new): The pharmaceutical composition of claim 168, wherein the pharmaceutical agent is an anticancer agent.

Claim 170 (new): The pharmaceutical composition of claim 168, wherein the pharmaceutical agent is an anti-inflammatory agent.

Claim 171 (new): The pharmaceutical composition of claim 168, wherein the pharmaceutical agent is an immunosuppressive agent.

Claim 172 (new): The pharmaceutical composition of claim 168, wherein the pharmaceutical agent is an antibiotic.

Claim 173 (new): The pharmaceutical composition of claim 168, wherein the pharmaceutical agent is rapamycin.

Claim 174 (new): The pharmaceutical composition of claim 168, wherein the pharmaceutical agent is vasoactive intestinal peptide.

Claim 175 (new): The pharmaceutical composition of claim 149, wherein the pharmaceutical agent is selected from the group consisting of anticancer agents, anesthetics, antimicrotubule agents, agents to treat cardiovascular disorders, antihypertensives, anti-inflammatory agents, anti-arthritic agents, antiasthmatics, analgesics, vasoactive agents, immunosuppressive agents, antifungal agents, antiarrhythmic agents, antibiotics, and hormones.

Claim 176 (new): The pharmaceutical composition of claim 175, wherein the pharmaceutical agent is an anticancer agent.

Claim 177 (new): The pharmaceutical composition of claim 175, wherein the pharmaceutical agent is an anti-inflammatory agent.

Claim 178 (new): The pharmaceutical composition of claim 175, wherein the pharmaceutical agent is an immunosuppressive agent.

Claim 179 (new): The pharmaceutical composition of claim 175, wherein the pharmaceutical agent is an antibiotic.

Claim 180 (new): The pharmaceutical composition of claim 175, wherein the pharmaceutical agent is rapamycin.

Claim 181 (new): The pharmaceutical composition of claim 175, wherein the pharmaceutical agent is vasoactive intestinal peptide.

Claim 182 (new): The pharmaceutical composition of claim 84, wherein the pharmaceutical agent is selected from the group consisting of anticancer agents, anesthetics, antimicrotubule agents, agents to treat cardiovascular disorders, antihypertensives, anti-inflammatory agents, anti-arthritic agents, antiasthmatics, analgesics, vasoactive agents, immunosuppressive agents, antifungal agents, antiarrhythmic agents, antibiotics, and hormones.

Claim 183 (new): The pharmaceutical composition of claim 182, wherein the pharmaceutical agent is an anticancer agent.

Claim 184 (new): The pharmaceutical composition of claim 182, wherein the pharmaceutical agent is an anti-inflammatory agent.

Claim 185 (new): The pharmaceutical composition of claim 182, wherein the pharmaceutical agent is an immunosuppressive agent.

Claim 186 (new): The pharmaceutical composition of claim 182, wherein the pharmaceutical agent is an antibiotic.

Claim 187 (new): The pharmaceutical composition of claim 182, wherein the pharmaceutical agent is rapamycin.

Claim 188 (new): The pharmaceutical composition of claim 182, wherein the pharmaceutical agent is vasoactive intestinal peptide.

Claim 189 (new): The pharmaceutical composition of claim 131, wherein the pharmaceutical agent is selected from the group consisting of anticancer agents, anesthetics, antimicrotubule agents, agents to treat cardiovascular disorders, antihypertensives, anti-inflammatory agents, anti-arthritic agents, antiasthmatics, analgesics, vasoactive agents, immunosuppressive agents, antifungal agents, antiarrhythmic agents, antibiotics, and hormones.

Claim 190 (new): The pharmaceutical composition of claim 189, wherein the pharmaceutical agent is an anticancer agent.

Claim 191 (new): The pharmaceutical composition of claim 189, wherein the pharmaceutical agent is an anti-inflammatory agent.

Claim 192 (new): The pharmaceutical composition of claim 189, wherein the pharmaceutical agent is an immunosuppressive agent.

Claim 193 (new): The pharmaceutical composition of claim 189, wherein the pharmaceutical agent is an antibiotic.

Claim 194 (new): The pharmaceutical composition of claim 189, wherein the pharmaceutical agent is rapamycin.

Claim 195 (new): The pharmaceutical composition of claim 189, wherein the pharmaceutical agent is vasoactive intestinal peptide.

Claim 196 (new): The pharmaceutical composition of claim 152, wherein the pharmaceutical agent is selected from the group consisting of anticancer agents, anesthetics, antimicrotubule agents, agents to treat cardiovascular disorders, antihypertensives, anti-inflammatory agents, anti-arthritic agents, antiasthmatics, analgesics, vasoactive agents, immunosuppressive agents, antifungal agents, antiarrhythmic agents, antibiotics, and hormones.

Claim 197 (new): The pharmaceutical composition of claim 196, wherein the pharmaceutical agent is an anticancer agent.

Claim 198 (new): The pharmaceutical composition of claim 196, wherein the pharmaceutical agent is an anti-inflammatory agent.

Claim 199 (new): The pharmaceutical composition of claim 196, wherein the pharmaceutical agent is an immunosuppressive agent.

Claim 200 (new): The pharmaceutical composition of claim 196, wherein the pharmaceutical agent is an antibiotic.

Claim 201 (new): The pharmaceutical composition of claim 196, wherein the pharmaceutical agent is rapamycin.

Claim 202 (new): The pharmaceutical composition of claim 196, wherein the pharmaceutical agent is vasoactive intestinal peptide.

Claim 203 (new): The pharmaceutical composition of claim 97, wherein the pharmaceutical agent is a taxane.

Claim 204 (new): The pharmaceutical composition of claim 203, wherein the taxane is paclitaxel.

Claim 205 (new): The pharmaceutical composition of claim 203, wherein the taxane is docetaxel.

Claim 206 (new): The pharmaceutical composition of claim 148, wherein the pharmaceutical agent is a taxane.

Claim 207 (new): The pharmaceutical composition of claim 206, wherein the taxane is paclitaxel.

Claim 208 (new): The pharmaceutical composition of claim 206, wherein the taxane is docetaxel.

Claim 209 (new): The pharmaceutical composition of claim 105, wherein the albumin and the pharmaceutical agent in the composition are formulated as nanoparticles.

Claim 210 (new): The pharmaceutical composition of claim 209, wherein the pharmaceutical agent is a taxane.

Claim 211 (new): The pharmaceutical composition of claim 210, wherein the taxane is paclitaxel.

Claim 212 (new): The pharmaceutical composition of claim 210, wherein the taxane is docetaxel.

Claim 213 (new): The pharmaceutical composition of claim 209, wherein the pharmaceutical agent is rapamycin.

Claim 214 (new): The pharmaceutical composition of claim 209, wherein the pharmaceutical agent is vasoactive intestinal peptide.

Claim 215 (new): The pharmaceutical composition of claim 110, wherein the albumin and the pharmaceutical agent in the composition are formulated as nanoparticles.

Claim 216 (new): The pharmaceutical composition of claim 119, wherein the albumin and the pharmaceutical agent in the composition are formulated as nanoparticles.

Claim 217 (new): The pharmaceutical composition of claim 130, wherein the albumin and the pharmaceutical agent in the composition are formulated as nanoparticles.

Claim 218 (new): The pharmaceutical composition of claim 139, wherein the albumin and the pharmaceutical agent in the composition are formulated as nanoparticles.

Claim 219 (new): The pharmaceutical composition of claim 97, wherein the albumin is human serum albumin.

Claim 220 (new): The pharmaceutical composition of claim 111, wherein the albumin is human serum albumin.

Claim 221 (new): The pharmaceutical composition of claim 120, wherein the albumin is human serum albumin.

Claim 222 (new): The pharmaceutical composition of claim 131, wherein the albumin is human serum albumin.

Claim 223 (new): The pharmaceutical composition of claim 140, wherein the albumin is human serum albumin.

Claim 224 (new): The pharmaceutical composition of claim 150, wherein the albumin is human serum albumin.

Claim 225 (new): The pharmaceutical composition of claim 153, wherein the albumin is human serum albumin.